Literature DB >> 8763345

MDR1/P-glycoprotein in haematological neoplasms.

J P Marie1, D C Zhou, S Gurbuxani, O Legrand, R Zittoun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8763345     DOI： 10.1016/0959-8049(96)00055-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  11 in total

1.  Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells.

Authors:  Katrina L Mealey; Rola Barhoumi; Robert C Burghardt; Stephen Safe; Deborah T Kochevar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.

Authors:  C Ustün; M Beksac; K Dalva; H Koc; N Konuk; O Ilhan; M Ozcan; P Topcuoglu; D Sertkaya; M Hayran
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

Authors:  Robert W Robey; Suneet Shukla; Elizabeth M Finley; Robert K Oldham; Daryl Barnett; Suresh V Ambudkar; Tito Fojo; Susan E Bates
Journal:  Biochem Pharmacol       Date:  2007-12-14       Impact factor: 5.858

Review 4.  Norcantharidin, derivative of cantharidin, for cancer stem cells.

Authors:  Chen-Hsi Hsieh; K S Clifford Chao; Hui-Fen Liao; Yu-Jen Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-02       Impact factor: 2.629

5.  Influence of RARalpha gene on MDR1 expression and P-glycoprotein function in human leukemic cells.

Authors:  Tatjana P Stromskaya; Ekaterina Y Rybalkina; Tatjana N Zabotina; Alexander A Shishkin; Alla A Stavrovskaya
Journal:  Cancer Cell Int       Date:  2005-05-24       Impact factor: 5.722

6.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

7.  The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.

Authors:  D Kostrzewa-Nowak; M J I Paine; C R Wolf; J Tarasiuk
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

8.  Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.

Authors:  M G Côme; A Skladanowski; A K Larsen; G Laurent
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid).

Authors:  Rameshwar Patil; Jose Portilla-Arias; Hui Ding; Bindu Konda; Arthur Rekechenetskiy; Satoshi Inoue; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Int J Mol Sci       Date:  2012-09-17       Impact factor: 6.208

10.  Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.

Authors:  G Lehne; H E Rugstad
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.